KR20130101031A - 핵산 포획 및 서열분석을 위한 방법 - Google Patents
핵산 포획 및 서열분석을 위한 방법 Download PDFInfo
- Publication number
- KR20130101031A KR20130101031A KR1020137007586A KR20137007586A KR20130101031A KR 20130101031 A KR20130101031 A KR 20130101031A KR 1020137007586 A KR1020137007586 A KR 1020137007586A KR 20137007586 A KR20137007586 A KR 20137007586A KR 20130101031 A KR20130101031 A KR 20130101031A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- genomic dna
- polymerase
- solid support
- immobilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 190
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 177
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 177
- 238000000034 method Methods 0.000 title claims abstract description 46
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 35
- 108020004414 DNA Proteins 0.000 claims description 130
- 239000012634 fragment Substances 0.000 claims description 86
- 125000003729 nucleotide group Chemical group 0.000 claims description 79
- 239000007787 solid Substances 0.000 claims description 79
- 239000002773 nucleotide Substances 0.000 claims description 78
- 238000009396 hybridization Methods 0.000 claims description 52
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 42
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 38
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 28
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 27
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 24
- 238000006116 polymerization reaction Methods 0.000 claims description 22
- 102100034343 Integrase Human genes 0.000 claims description 18
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 229940104302 cytosine Drugs 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 238000010348 incorporation Methods 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 6
- 230000003100 immobilizing effect Effects 0.000 claims description 5
- 230000011987 methylation Effects 0.000 abstract description 13
- 238000007069 methylation reaction Methods 0.000 abstract description 13
- 230000000295 complement effect Effects 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 20
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 239000002299 complementary DNA Substances 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 239000011324 bead Substances 0.000 description 13
- 238000012544 monitoring process Methods 0.000 description 13
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 12
- 239000000758 substrate Substances 0.000 description 11
- 238000002493 microarray Methods 0.000 description 9
- 229940035893 uracil Drugs 0.000 description 9
- 238000003491 array Methods 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 235000021317 phosphate Nutrition 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- -1 bisulfite ions Chemical class 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 238000002966 oligonucleotide array Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 238000002165 resonance energy transfer Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- LPHFLPKXBKBHRW-UHFFFAOYSA-L magnesium;hydrogen sulfite Chemical compound [Mg+2].OS([O-])=O.OS([O-])=O LPHFLPKXBKBHRW-UHFFFAOYSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40235010P | 2010-08-27 | 2010-08-27 | |
| US61/402,350 | 2010-08-27 | ||
| PCT/US2011/049151 WO2012027572A2 (en) | 2010-08-27 | 2011-08-25 | Methods for nucleic acid capture and sequencing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130101031A true KR20130101031A (ko) | 2013-09-12 |
Family
ID=44545975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137007586A Withdrawn KR20130101031A (ko) | 2010-08-27 | 2011-08-25 | 핵산 포획 및 서열분석을 위한 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130324419A1 (enExample) |
| EP (1) | EP2609214A2 (enExample) |
| JP (1) | JP2013535986A (enExample) |
| KR (1) | KR20130101031A (enExample) |
| CN (1) | CN103080338A (enExample) |
| BR (1) | BR112013002299A2 (enExample) |
| CA (1) | CA2803693A1 (enExample) |
| MX (1) | MX2013001799A (enExample) |
| RU (1) | RU2013113407A (enExample) |
| WO (1) | WO2012027572A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9074251B2 (en) | 2011-02-10 | 2015-07-07 | Illumina, Inc. | Linking sequence reads using paired code tags |
| WO2012106546A2 (en) | 2011-02-02 | 2012-08-09 | University Of Washington Through Its Center For Commercialization | Massively parallel continguity mapping |
| NO2694769T3 (enExample) | 2012-03-06 | 2018-03-03 | ||
| EP2875173B1 (en) * | 2012-07-17 | 2017-06-28 | Counsyl, Inc. | System and methods for detecting genetic variation |
| US9683230B2 (en) | 2013-01-09 | 2017-06-20 | Illumina Cambridge Limited | Sample preparation on a solid support |
| EP2970951B1 (en) | 2013-03-13 | 2019-02-20 | Illumina, Inc. | Methods for nucleic acid sequencing |
| AU2014364926B2 (en) | 2013-12-20 | 2017-12-14 | Illumina, Inc. | Preserving genomic connectivity information in fragmented genomic DNA samples |
| KR102472027B1 (ko) * | 2014-10-17 | 2022-11-30 | 일루미나 케임브리지 리미티드 | 근접 보존 전위 |
| PT3207134T (pt) * | 2014-10-17 | 2019-09-17 | Illumina Cambridge Ltd | Transposição que preserva a contiguidade |
| US9859394B2 (en) | 2014-12-18 | 2018-01-02 | Agilome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
| US9618474B2 (en) | 2014-12-18 | 2017-04-11 | Edico Genome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
| US9857328B2 (en) | 2014-12-18 | 2018-01-02 | Agilome, Inc. | Chemically-sensitive field effect transistors, systems and methods for manufacturing and using the same |
| US10006910B2 (en) | 2014-12-18 | 2018-06-26 | Agilome, Inc. | Chemically-sensitive field effect transistors, systems, and methods for manufacturing and using the same |
| EP3235010A4 (en) | 2014-12-18 | 2018-08-29 | Agilome, Inc. | Chemically-sensitive field effect transistor |
| US10020300B2 (en) | 2014-12-18 | 2018-07-10 | Agilome, Inc. | Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids |
| US10395759B2 (en) * | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
| WO2017201081A1 (en) | 2016-05-16 | 2017-11-23 | Agilome, Inc. | Graphene fet devices, systems, and methods of using the same for sequencing nucleic acids |
| EP3650553B1 (en) * | 2018-11-07 | 2023-07-12 | Siemens Healthcare GmbH | Method for detection of specific nucleic acids |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO165894C (no) * | 1988-05-24 | 1991-04-24 | Gunnar Paulsen | Analysemetode for gener. |
| US6982146B1 (en) * | 1999-08-30 | 2006-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | High speed parallel molecular nucleic acid sequencing |
| WO2008115185A2 (en) | 2006-04-24 | 2008-09-25 | Nimblegen Systems, Inc. | Use of microarrays for genomic representation selection |
| WO2008096146A1 (en) * | 2007-02-07 | 2008-08-14 | Solexa Limited | Preparation of templates for methylation analysis |
| WO2008103848A1 (en) * | 2007-02-21 | 2008-08-28 | Invitrogen Corporation | Materials and methods for single molecule nucleic acid sequencing |
| WO2009024019A1 (en) * | 2007-08-15 | 2009-02-26 | The University Of Hong Kong | Methods and compositions for high-throughput bisulphite dna-sequencing and utilities |
| US20110281740A1 (en) | 2008-06-30 | 2011-11-17 | Joseph Beechem | Methods for Real Time Single Molecule Sequencing |
| US8795961B2 (en) * | 2008-09-05 | 2014-08-05 | Pacific Biosciences Of California, Inc. | Preparations, compositions, and methods for nucleic acid sequencing |
| WO2010085343A1 (en) | 2009-01-23 | 2010-07-29 | Cold Spring Harbor Laboratory | Methods and arrays for profiling dna methylation |
-
2011
- 2011-08-25 RU RU2013113407/10A patent/RU2013113407A/ru not_active Application Discontinuation
- 2011-08-25 MX MX2013001799A patent/MX2013001799A/es not_active Application Discontinuation
- 2011-08-25 BR BR112013002299A patent/BR112013002299A2/pt not_active IP Right Cessation
- 2011-08-25 EP EP11752056.9A patent/EP2609214A2/en not_active Withdrawn
- 2011-08-25 CA CA2803693A patent/CA2803693A1/en not_active Abandoned
- 2011-08-25 JP JP2013526153A patent/JP2013535986A/ja active Pending
- 2011-08-25 KR KR1020137007586A patent/KR20130101031A/ko not_active Withdrawn
- 2011-08-25 US US13/819,657 patent/US20130324419A1/en not_active Abandoned
- 2011-08-25 CN CN2011800416596A patent/CN103080338A/zh active Pending
- 2011-08-25 WO PCT/US2011/049151 patent/WO2012027572A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013113407A (ru) | 2014-10-10 |
| BR112013002299A2 (pt) | 2016-05-24 |
| CN103080338A (zh) | 2013-05-01 |
| MX2013001799A (es) | 2013-05-20 |
| WO2012027572A3 (en) | 2012-06-07 |
| EP2609214A2 (en) | 2013-07-03 |
| US20130324419A1 (en) | 2013-12-05 |
| JP2013535986A (ja) | 2013-09-19 |
| WO2012027572A2 (en) | 2012-03-01 |
| CA2803693A1 (en) | 2012-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20130101031A (ko) | 핵산 포획 및 서열분석을 위한 방법 | |
| US12480159B2 (en) | Compositions containing identifier sequences on solid supports for nucleic acid sequence analysis | |
| KR101994494B1 (ko) | 조직 샘플 중의 핵산의 국지적 또는 공간적 검출을 위한 방법 및 그 방법의 생성물 | |
| US9932576B2 (en) | Methods for targeted genomic analysis | |
| US20180334705A1 (en) | Methods for Making Nucleotide Probes for Sequencing and Synthesis | |
| US8329394B2 (en) | Methods and substances for isolation and detection of small polynucleotides | |
| US20090061424A1 (en) | Universal ligation array for analyzing gene expression or genomic variations | |
| EP3191604A1 (en) | Methods and compositions for rapid nucleic acid library preparation | |
| CA2810931A1 (en) | Direct capture, amplification and sequencing of target dna using immobilized primers | |
| CZ20011183A3 (cs) | Způsob amplifikace a sekvenování nukleové kyseliny | |
| KR20230124636A (ko) | 멀티플렉스 반응에서 표적 서열의 고 감응성 검출을위한 조성물 및 방법 | |
| US20240167088A1 (en) | Methods and devices of generating clusters of amplicons | |
| HK1184831A (en) | Methods for nucleic acid capture and sequencing | |
| HK40117503A (en) | Single molecule nucleic acid sequence analysis processes and compositions | |
| HK40028998B (en) | Single molecule nucleic acid sequence analysis processes and compositions | |
| HK40028998A (en) | Single molecule nucleic acid sequence analysis processes and compositions | |
| HK1257956B (en) | Single molecule nucleic acid sequence analysis processes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130326 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |